Y-Mabs Therapeutics Completes Merger with Perseus BidCo

Y-Mabs Therapeutics ( (YMAB) ) has issued an announcement.

On September 16, 2025, Y-mAbs Therapeutics, Inc. completed a merger with Perseus BidCo US, Inc., resulting in Y-mAbs becoming a wholly owned subsidiary. The merger followed a successful cash tender offer where 87.22% of outstanding shares were tendered, leading to a transaction valued at approximately $413 million. Consequently, Y-mAbs requested the delisting of its shares from Nasdaq and the resignation of its board and executive officers, who were replaced by new appointees from the acquiring company.

The most recent analyst rating on (YMAB) stock is a Hold with a $8.60 price target. To see the full list of analyst forecasts on Y-Mabs Therapeutics stock, see the YMAB Stock Forecast page.

Spark’s Take on YMAB Stock

According to Spark, TipRanks’ AI Analyst, YMAB is a Neutral.

Y-Mabs Therapeutics faces significant challenges with profitability and cash flow despite revenue growth. The technical analysis indicates a bearish trend, and the valuation is not compelling due to negative earnings. While the earnings call presented some positive developments, the strategic realignment must address key challenges to improve the outlook.

To see Spark’s full report on YMAB stock, click here.

More about Y-Mabs Therapeutics

Y-mAbs Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel antibody-based products for the treatment of cancer. The company operates within the healthcare industry, specifically targeting oncology therapeutics.

Average Trading Volume: 905,075

Technical Sentiment Signal: Buy

Current Market Cap: $391.2M

For detailed information about YMAB stock, go to TipRanks’ Stock Analysis page.